Soligenix (NASDAQ:SNGX) and Zura Bio (NASDAQ:ZURA) Critical Analysis

Zura Bio (NASDAQ:ZURA) and Soligenix (NASDAQ:SNGX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, analyst recommendations, profitability and dividends.

Profitability

This table compares Zura Bio and Soligenix’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zura Bio	N/A	-56.13%	-50.15%
Soligenix	N/A	-180.25%	-107.46%

Volatility and Risk

Zura Bio has a beta of -0.02, suggesting that its stock price is 102% less volatile than the S&P 500. Comparatively, Soligenix has a beta of 1.93, suggesting that its stock price is 93% more volatile than the S&P 500.

Institutional and Insider Ownership

61.1% of Zura Bio shares are owned by institutional investors. Comparatively, 3.6% of Soligenix shares are owned by institutional investors. 12.4% of Zura Bio shares are owned by insiders. Comparatively, 1.9% of Soligenix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current recommendations and price targets for Zura Bio and Soligenix, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zura Bio	1	0	5	1	2.86
Soligenix	1	0	0	0	1.00

Zura Bio currently has a consensus target price of $17.00, suggesting a potential upside of 197.20%. Given Zura Bio’s stronger consensus rating and higher probable upside, equities analysts plainly believe Zura Bio is more favorable than Soligenix.

Earnings and Valuation

This table compares Zura Bio and Soligenix”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zura Bio	N/A	N/A	-$99.35 million	($1.13)	-5.06
Soligenix	$120,000.00	46.53	-$11.08 million	($0.98)	-0.38

Soligenix has higher revenue and earnings than Zura Bio. Zura Bio is trading at a lower price-to-earnings ratio than Soligenix, indicating that it is currently the more affordable of the two stocks.

Summary

Zura Bio beats Soligenix on 8 of the 13 factors compared between the two stocks.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.

About Soligenix

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia, Ib, and Ic clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.